Optimizing low-technology metofluthrin emanators to extend active ingredient release while maximizing protection against malaria transmission
Optimizing low-technology metofluthrin emanators to extend active ingredient release while maximizing protection against malaria transmission
批准号:
MR/N027442/1
负责人:
Gerry Killeen
金额:
$12.64万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We recently developed a low-technology emanator consisting of commonly available Hessian sacking impregnated with the widely-used volatile pyrethroid transfluthrin, which is slowly released into the air as a vapour. These emanators protected humans against behaviourally and physiologically resistant Anopheles arabiensis indoors and outdoors for over 2 years and killed the vast majority of mosquitoes that succeeded in feeding on protected humans. The disadvantage of transfluthrin is its relatively high melting point, which limits its vapour pressure and efficacy outside of low-altitude equatorial settings with very high night time temperatures. Fortunately, a similarly safe volatile pyrethroid called metofluthrin is also available from generic sources, which has a lower melting point so it remains volatile across the full range of temperatures relevant to malaria transmission.We therefore propose to repeat dose-optimization for this emanator prototype with metofluthrin, rather than transfluthrin, using a range of thicknesses of diffusion-retarding plastic coatings. Our primary objective is to identify the minimum dose, and optimal coating thickness at that dose, which confers at least 80% protection against exposure to biting An. arabiensis, as well as An. gambiae and An. funestus, for at least one year. Our secondary objective is to demonstrate that predicted maximum cost per year of protection is comparable with those for long-lasting insecticidal nets.If both objectives are achieved, this early phase study will be followed by an application to conduct the main study: a community-randomized controlled trial to assess impact upon malaria incidence among both users and non-users, supplemented with participatory social science studies of end-user perceptions. Both studies will be conducted in a relatively high altitude (1100m) region of west Kenya with moderate temperatures.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Durable, practical, effective and affordable formats for insecticide-treated eave baffles that protect households and suppress malaria transmission
-
批准号:MR/P01691X/1
-
项目类别:Research Grant
-
资助金额:$19.27万
-
财政年份:2017
-
负责人:Gerry Killeen
-
依托单位:
Zika: Affordable, scalable, low-technology transfluthrin emanators for protecting against transmission in low-income countries
-
批准号:MC_PC_15086
-
项目类别:Intramural
-
资助金额:$18.98万
-
财政年份:2016
-
负责人:Gerry Killeen
-
依托单位:
国内基金
海外基金
登录
查看更多内容
骨髓微环境中正常造血干/祖细胞新亚群IL7Rα(-)LSK(low)细胞延缓急性髓系白血病进程的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王震毅
-
依托单位:
MSCEN聚集体抑制CD127low单核细胞铜死亡治疗SLE 的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:耿林玉
-
依托单位:
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
-
批准号:82371631
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:卢慕峻
-
依托单位:
Ni-20Cr合金梯度纳米结构的低温构筑及其腐蚀行为研究
-
批准号:52301123
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:郭晓开
-
依托单位:
LIPUS促进微环境巨噬细胞释放CCL2诱导尿道周围平滑肌祖细胞定植与分化的机制研究
-
批准号:82370780
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:夏术阶
-
依托单位:
新型PDL1+CXCR2low中性粒细胞在脉络膜新生血管中的作用及机制研究
-
批准号:82271095
-
项目类别:面上项目
-
资助金额:56万元
-
批准年份:2022
-
负责人:柳夏林
-
依托单位:
CD9+CD55low脂肪前体细胞介导高脂诱导脂肪组织炎症和2型糖尿病的作用和机制研究
-
批准号:82270883
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:毕艳
-
依托单位:
CD21low/-CD23-B细胞亚群在间质干细胞治疗慢性移植物抗宿主病中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈小湧
-
依托单位:
探究Msi1+Lgr5neg/low肠道干细胞抵抗辐射并驱动肠上皮再生的新机制
-
批准号:82270588
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:吕聪
-
依托单位:
m6A去甲基化酶FTO通过稳定BRD9介导表观重塑在HIF2α(low/-)肾透明细胞癌中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:54.7万元
-
批准年份:2021
-
负责人:徐丹枫
-
依托单位: